EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis

Arun George Devasia, Adaikalavan Ramasamy, Chen Huei Leo iD

International Journal of Molecular Sciences · 19.02.2025 · 26 (4) · 1778

DOI: 10.3390/ijms26041778 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.02.2025. Verfasst von Arun George Devasia und 2 weiteren Autor:innen. Beteiligte Einrichtung: Science, Math & Technology, Singapore University of Technology & Design, Singapore 487372, Singapore. Hauptthemen laut MEDLINE: Fatty Liver, Metabolic Diseases, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 333 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, “metabolic dysfunction-associated steatotic liver disease” (MASLD) has been proposed to better connect liver disease to metabolic dysfunction, which is the most common chronic liver disease worldwide. MASLD affects more than 30% of individuals globally, and it is diagnosed by the combination of hepatic steatosis and obesity, type 2 diabetes, or two metabolic risk factors. MASLD begins with the buildup of extra fat, often greater than 5%, within the liver, causing liver hepatocytes to become stressed. This can proceed to a more severe form, metabolic dysfunction-associated steatohepatitis (MASH), in 20–30% of people, where inflammation in the liver causes tissue fibrosis, which limits blood flow over time. As fibrosis worsens, MASH may lead to cirrhosis, liver failure, or even liver cancer. While the pathophysiology of MASLD is not fully known, the current “multiple-hits” concept proposes that dietary and lifestyle factors, metabolic factors, and genetic or epigenetic factors contribute to elevated oxidative stress and inflammation, causing liver fibrosis. This review article provides an overview of the pathogenesis of MASLD and evaluates existing therapies as well as pharmacological drugs that are currently being studied in clinical trials for MASLD or MASH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverMetabolic DiseasesNon-alcoholic Fatty Liver DiseaseHumansAnimalsOxidative StressLiver CirrhosisLiverObesity

Stichwörter der Autor:innen

metabolic dysfunction-associated steatohepatitismetabolic dysfunction-associated steatotic liver diseasenon-alcoholic fatty liver diseasetherapeutics

Autor:innen und Institutionen

  • Science, Math & Technology, Singapore University of Technology & Design, Singapore 487372, Singapore.
  • Genome Institute of Singapore (GIS), Agency for Science Technology and Research (A*STAR), 60 Biopolis Street, Singapore 138672, Singapore.
  • Department of Biomedical Engineering, College of Design & Engineering, National University of Singapore, 9 Engineering Drive 1, Singapore 117576, Singapore.

ORCID-Profile: Chen Huei Leo

Zitieren

APA

Devasia, A. G., Ramasamy, A., & Leo, C. H. (2025). Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis. International Journal of Molecular Sciences, 26(4), 1778. https://doi.org/10.3390/ijms26041778

Vancouver

Devasia AG, Ramasamy A, Leo CH. Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis. International Journal of Molecular Sciences. 2025;26(4):1778. doi:10.3390/ijms26041778

BibTeX
@article{Devasia2025,
  author = {Devasia, Arun George and Ramasamy, Adaikalavan and Leo, Chen Huei},
  title = {Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {4},
  pages = {1778},
  doi = {10.3390/ijms26041778}
}
Kostenlos starten →